Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.The Motley Fool • 10/11/26
Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase24/7 Wall Street • 10/07/26
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026PRNewsWire • 10/05/26
Grail's cancer blood test nears landmark FDA approval, but insurance coverage loomsReuters • 10/02/26
Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next.Investors Business Daily • 09/30/26
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.The Motley Fool • 09/30/26
Grail Surges After FDA Advisors Back Its Cancer-Finding Blood TestInvestors Business Daily • 09/24/26
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection TestPRNewsWire • 09/23/26
FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.Market Watch • 09/23/26
GRAIL: Stock Surges As Market Digests FDA Briefing Docs - I Broadly Concur (Rating Upgrade)Seeking Alpha • 09/21/26